🇺🇸 FDA
Pipeline program

A Study to Assess Distribution, Binding, and Retention of the Monoclonal Antibody Trontinemab in the Brain of Healthy Participants and Patients with Alzheimer’s Disease

BP45211

Phase 1 other active

Quick answer

A Study to Assess Distribution, Binding, and Retention of the Monoclonal Antibody Trontinemab in the Brain of Healthy Participants and Patients with Alzheimer’s Disease for Alzheimer’s Disease (AD) is a Phase 1 program (other) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Roche Registration Limited
Indication
Alzheimer’s Disease (AD)
Phase
Phase 1
Modality
other
Status
active

Clinical trials